Canagliflozin reduces the overall risk of heart failure (HF) events in patients with type 2 diabetes and high cardiovascular risk, irrespective of ejection fraction. An Australian-led study, published in Circulation and presented at the American College of Cardiology meeting in New Orleans, found no clear difference in effects based on reduced (HFrEF) versus preserved (HFpEF) ...
SGLT2 inhibitor effective against HF regardless of ejection fraction
By Mardi Chapman
20 Mar 2019